• Drug: Simponi (golimumab)
  • Manufacturer: Johnson & Johnson

  • Route of Administration: Subcutaneous

  • Site of Care: Outpatient
  • Approved Indication:

      • treatment of adult patients with moderately to severely active rheumatoid arthritis in combination with methotrexate
      • treatment of adult patients with active psoriatic arthritis alone, or in combination with methotrexate
      • treatment of adult patients with active ankylosing spondylitis
      • inducing and maintaining clinical response, improving endoscopic appearance of the mucosa during induction, achieving clinical remission, and achieving and sustaining clinical remission in induction responders in adult patients with moderately to severely active ulcerative colitis with an inadequate response or intolerance to prior treatment or requiring continuous steroid therapy
  • Disease: ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis
  • Therapeutic Area: Gastroenterology, Rheumatology, Dermatology
  • Enrollment Form Link: www.simponihcp.com/resources
  • Phone Number: 1-877-CarePath (1-877-227-3728)

  • Fax Number: N/A

  • Product Website: simponi.com